The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
PIT-2: A multicenter phase II trail of S-1 plus cisplatin with concurrent radiotherapy followed by surgery in stage IIIA (N2) lung squamous cell carcinoma.
 
Kazuya Takamochi
No Relationships to Disclose
 
Masahiro Tsuboi
Honoraria - AstraZeneca Japan; Bristol-Myers Squibb Japan; Chugai Pharma; Johnson & Johnson; Medtronic; MSD K.K; Novartis; Ono Pharmaceutical; Taiho Pharmaceutical; Teijin Pharma
Research Funding - Boehringer Ingelheim (Inst); Merck (Inst)
 
Morihito Okada
Speakers' Bureau - AstraZeneca; Chugai Pharma; Covidien; CSL Behring; Johnson & Johnson; Lilly; Ono Pharmaceutical; Taiho Pharmaceutical
Research Funding - Chugai Pharma (Inst); Covidien (Inst); Daiichi Sankyo (Inst); Johnson & Johnson (Inst); Kyowa Hakko Kirin (Inst); Lilly Japan (Inst); Mochida Pharmaceutical Co. Ltd. (Inst); Nihon Medi-Physics (Inst); Nippon Kayaku (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Yakult Honsha (Inst)
 
Seiji Niho
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Janssen; Kyorin; Lilly Japan; MSD; Novartis; Ono Pharmaceutical; Pfizer; Taiho Pharmaceutical
Consulting or Advisory Role - Pfizer
Research Funding - AstraZeneca (Inst); Boehringer Ingelheim (Inst); Chugai Pharma (Inst); Lilly (Inst); Merck Serono (Inst); MSD (Inst); Ono Pharmaceutical (Inst); Pfizer (Inst); Sanofi (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst); Takeda (Inst); Teijin Pharma (Inst)
 
Satoshi Ishikura
No Relationships to Disclose
 
Shunsuke Oyamada
No Relationships to Disclose
 
Takuhiro Yamaguchi
Stock and Other Ownership Interests - STATCOM
Consulting or Advisory Role - CAC Croit Corporation; Japan Tobacco Inc; Kowa; Ono Pharmaceutical
Speakers' Bureau - Asahi Kasei; Daiichi Sankyo; Nipro Corporation; Takeda; Tsumura & Co.
Research Funding - 3H Clinical Trial; 3H Medi Solution (Inst); A2 Healthcare (Inst); AC Medical (Inst); ClinChoice; Eisai; Facet Biotech (Inst); Hemp Kitchen (Inst); intellim (Inst); Japan Media Corporation (Inst); Japan Tobacco Inc (Inst); Medidata Solutions, Inc (Inst); Medrio (Inst); NIPRO CORPORATION (Inst); Nobori Ltd. (Inst); Ono Pharmaceutical (Inst); Otsuka; Puravida Technologies (Inst); Senju Pharmaceutical; Welby (Inst)
 
Fumihiro Tanaka
No Relationships to Disclose
 
Ichiro Yoshino
Honoraria - AstraZeneca; Boehringer Ingelheim; Chugai Pharma; Covidien/Medtronic; Daiichi Sankyo; Intuitive Surgical; Johnson & Johnson; Pfizer; Shionogi; Taiho Pharmaceutical
Consulting or Advisory Role - AstraZeneca; Covidien/Medtronic; Intuitive Surgical
Research Funding - Chugai Pharma (Inst); Pfizer (Inst); Shionogi (Inst); Taiho Pharmaceutical (Inst)
 
Masanori Tsuchida
No Relationships to Disclose
 
Satoshi Shiono
No Relationships to Disclose
 
Hiroyuki Oizumi
No Relationships to Disclose
 
Norihito Okumura
No Relationships to Disclose
 
Tomohiro Haruki
No Relationships to Disclose
 
Kenji Suzuki
No Relationships to Disclose